Active, Not Recruiting
Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors
NCT04669496
- Conditions
- Adenocarcinoma, Carcinoma, Cholangiocarcinoma, +7 more
- Locations
-
- Zhongshan hospital Shanghai, Shanghai Municipality, China